[{"address1": "830 Winter Street", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "781 999 0232", "website": "https://www.q32bio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti\u0096interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb \u0096 CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.", "fullTimeEmployees": 26, "companyOfficers": [{"maxAge": 1, "name": "Ms. Jodie Pope Morrison", "age": 49, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 860740, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Lee H. Kalowski M.B.A.", "age": 44, "title": "CFO & President", "yearBorn": 1981, "fiscalYear": 2024, "totalPay": 750793, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shelia M. Violette Ph.D.", "age": 64, "title": "Co-founder, Chief Scientific Officer & President of Research", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 619930, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David  Appugliese J.D.", "title": "Senior VP & Head of People", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria  Marzilli M.P.H.", "title": "Chief Business Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Adrien  Sipos", "title": "Interim Chief Medical Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.27, "open": 4.14, "dayLow": 4.01, "dayHigh": 4.7, "regularMarketPreviousClose": 4.27, "regularMarketOpen": 4.14, "regularMarketDayLow": 4.01, "regularMarketDayHigh": 4.7, "payoutRatio": 0.0, "forwardPE": -0.875, "volume": 225879, "regularMarketVolume": 225879, "averageVolume": 3136036, "averageVolume10days": 176050, "averageDailyVolume10Day": 176050, "bid": 4.59, "ask": 4.74, "bidSize": 1, "askSize": 1, "marketCap": 57707412, "fiftyTwoWeekLow": 1.345, "fiftyTwoWeekHigh": 6.37, "allTimeHigh": 572.4, "allTimeLow": 1.345, "fiftyDayAverage": 3.5576, "twoHundredDayAverage": 2.441175, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 25693410, "profitMargins": 0.0, "floatShares": 7043626, "sharesOutstanding": 12304352, "sharesShort": 308671, "sharesShortPriorMonth": 282006, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.0251, "heldPercentInsiders": 0.0554, "heldPercentInstitutions": 0.58892, "shortRatio": 1.86, "shortPercentOfFloat": 0.0872, "impliedSharesOutstanding": 12304352, "bookValue": -1.499, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -42098000, "trailingEps": -3.4, "forwardEps": -5.36, "lastSplitFactor": "1:18", "lastSplitDate": 1711411200, "enterpriseToEbitda": -0.596, "52WeekChange": 0.49425292, "SandP52WeekChange": 0.11527538, "quoteType": "EQUITY", "currentPrice": 4.69, "targetHighPrice": 20.0, "targetLowPrice": 10.0, "targetMeanPrice": 15.0, "targetMedianPrice": 15.0, "recommendationKey": "none", "numberOfAnalystOpinions": 2, "totalCash": 49039000, "totalCashPerShare": 3.986, "ebitda": -43082000, "totalDebt": 17025000, "quickRatio": 4.464, "currentRatio": 4.573, "returnOnAssets": -0.335, "grossProfits": -26386000, "freeCashflow": -24365876, "operatingCashflow": -38791000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "QTTB", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1522243800000, "postMarketChangePercent": 0.8528776, "postMarketPrice": 4.73, "postMarketChange": 0.03999996, "regularMarketChange": 0.42, "regularMarketDayRange": "4.01 - 4.7", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 3136036, "fiftyTwoWeekLowChange": 3.345, "fiftyTwoWeekLowChangePercent": 2.4869888, "fiftyTwoWeekRange": "1.345 - 6.37", "fiftyTwoWeekHighChange": -1.6799998, "fiftyTwoWeekHighChangePercent": -0.26373625, "fiftyTwoWeekChangePercent": 49.425293, "earningsTimestampStart": 1762432200, "earningsTimestampEnd": 1762432200, "isEarningsDateEstimate": true, "longName": "Q32 Bio Inc.", "epsTrailingTwelveMonths": -3.4, "epsForward": -5.36, "fiftyDayAverageChange": 1.1324, "fiftyDayAverageChangePercent": 0.31830448, "twoHundredDayAverageChange": 2.248825, "twoHundredDayAverageChangePercent": 0.921206, "priceToBook": -3.1287527, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "shortName": "Q32 Bio Inc.", "cryptoTradeable": false, "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1771635076, "regularMarketTime": 1771621201, "exchange": "NCM", "messageBoardId": "finmb_669405676", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 9.83607, "regularMarketPrice": 4.69, "displayName": "Q32 Bio", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]